Our study builds on a patented IHC methodology (Malaysian Patent Application No. PI2024002978), titled “Method for Detecting the Expression of NUB1 in Human Tumour Tissue”, filed on 1 May 2024, and developed as part of this research study. Here, NUB1 is linked to neoplasm.